Skip to Content

Cronos Group Inc CRON

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Low Probability and Materiality of ESG Risks Leaves Cronos’ FVE and Uncertainty Rating Intact

Analyst Note

| Kristoffer Inton |

After updating Cronos for our latest methodologies, we find minimal valuation impact from environmental, social, and governance risk and assign a Standard capital allocation rating. We maintain our $7 and CAD 9 per share fair value estimates and no-moat rating. Shares look slightly undervalued but in 3-star territory after considering Cronos’ very high uncertainty rating.

Read Full Analysis

Company Profile

Business Description

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

111 Peter Street, Suite 300
Toronto, ON, M5V2G9, Canada
T +1 416 504-0004
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 665